Sanofi India (500674) investor relations material

Executive summary

• Year marked by significant transformation, including business model modernization, strategic demerger of the Consumer Healthcare business effective June 1, 2024, and ongoing stabilization into 2025 and 2026.

• Focus on sustainable, profitable growth through R&D-driven, AI-enabled, and patient-centric operations, with strong execution in India's diabetes market.

• Diabetes franchise maintained leadership, with Lantus holding 31% market share and Toujeo showing double-digit growth; Soliqua positioned for further acceleration.

• Statutory auditors issued an unmodified opinion on the financial statements.

• Board recommended a total dividend of ₹123 per share for 2025, subject to shareholder approval.

Financial highlights

• Revenue from operations for 2025 was ₹18,374 million, down from ₹20,132 million in 2024; total income for FY 2025 was ₹18,571 million, down 9% year-over-year.

• Net profit from continuing operations for 2025 was ₹3,267 million, up from ₹3,137 million in 2024.

• Profit before tax and exceptional items for FY 2025 was ₹4,720 million, up 1% year-over-year.

• Operating expenses reduced by 17% both for the quarter and full year compared to 2024.

• Export sales declined by ₹1,481 million year-over-year due to the end of a contract with Zentiva and prior divestment of the Ankleshwar site.

Outlook and guidance

• Partnership sales expected to remain volatile through 2026 due to inventory and stock replenishment cycles.

• Diabetes business expected to continue double-digit growth, especially with Soliqua and Toujeo expansion.

• No new product launches planned for 2026; focus remains on maximizing current portfolio and public sector expansion.

• The company will assess the final impact of new Labour Codes on employee benefit obligations once official rules are notified.